Table 1 Selected baseline characteristics in the development and validation cohorts
Characteristic | Development cohort (n = 49,612) | Validation cohort (n = 12,402) |
|---|---|---|
Demographics | ||
Age in years, mean (SD) | 82.6 (4.8) | 82.5 (4.8) |
Male | 48,918 (98.6%) | 12,204 (98.4%) |
Vital Signs | ||
BMI ≥30 | 9278 (18.7%) | 2332 (18.8%) |
SBP ≥140 mmHg | 14,877 (30.0%) | 3793 (30.6%) |
Medications | ||
Lipid lowering agents | 27,138 (54.7%) | 6797 (54.8%) |
ACE inhibitors | 12,552 (25.3%) | 3200 (25.8%) |
Beta blockers | 17,563 (35.4%) | 4304 (34.7%) |
Oral hypoglycemics | 7343 (14.8%) | 1861 (15.0%) |
Chronic Conditions | ||
Hypertension | 37,927 (76.5%) | 9507 (76.7%) |
Hyperlipidemia | 35,420 (71.4%) | 8872 (71.5%) |
Diabetes mellitus | 17,736 (35.8%) | 4360 (35.2%) |
Congestive heart failure | 6046 (12.2%) | 1430 (11.5%) |
Dementia | 4616 (9.3%) | 1167 (9.4%) |
VA utilization | ||
Emergency department visits | ||
0 | 43,986 (88.7%) | 10,982 (88.6%) |
1 | 3134 (6.3%) | 787 (6.4%) |
> 1 | 2492 (5.0%) | 633 (5.1%) |
Hospitalizations | ||
0 | 47,174 (95.1%) | 11,758 (94.8%) |
1 | 1794 (3.6%) | 473 (3.8%) |
> 1 | 644 (1.3%) | 171 (1.4%) |
Functional scores, median (IQR) | ||
ADL score (range, 0-5) | 0 (0-0) | 0 (0-0) |
IADL score (range, 0-7) | 0 (0-1) | 0 (0-1) |
Medicare linkage available | 20,058 (40.4%) | 5045 (40.7%) |
Medicare utilization | ||
Emergency department visits | ||
0 | 39,643 (79.9%) | 9938 (80.1%) |
1 | 5870 (11.8%) | 1504 (12.1%) |
> 1 | 4099 (8.3%) | 960 (7.7%) |
Hospitalizations | ||
0 | 44,236 (89.2%) | 11,120 (89.7%) |
1 | 3749 (7.6%) | 899 (7.2%) |
> 1 | 1627 (3.3%) | 393 (3.2%) |
Mortality at follow-up | ||
Year 1 | 3969 (8.0%) | 993 (8.0%) |
Year 2 | 8137 (16.4%) | 2021 (16.3%) |
Year 3 | 12,503 (25.2%) | 3101 (25.0%) |
Year 4 | 16,720 (33.7%) | 4155 (33.5%) |
Year 5 | 20,738 (41.8%) | 5185 (41.8%) |